Experimental virus therapy takes on deadly brain cancer

NCT ID NCT06102525

Recruiting now Disease control Sponsor: Rznomics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing a new treatment for glioblastoma, an aggressive brain cancer. The therapy uses a modified virus (RZ-001) that is injected into the tumor, followed by an antiviral drug (valganciclovir) designed to activate the virus and kill cancer cells. The study will enroll 43 adults to check safety and see if the treatment has any effect on the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RZ-001 (a modified virus) plus valganciclovir (an antiviral drug)
What this could lead to: If it works, this could point toward a new treatment option for glioblastoma, a tough brain cancer.
What could go wrong: This is a very early (Phase 1/2a) and small trial (43 people). The treatment may not shrink tumors or improve survival, and could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Gachon University Gil Medical Center
RECRUITING

Incheon, 21565, South Korea
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, 13620, South Korea
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
The Catholic University of Korea, Incheon St. Mary's Hospital
RECRUITING

Incheon, 21431, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.